fashion -WSS

fashion

author：Wikipedia 2025-09-28 01:35:05 - browse：92313

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： South Korea throws huge K

knowledge

Wikipedia

WSS

Nobel honors Karikó and Weissman's enduring partnership

Will an HIV vaccine ever be a reality?

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

How to use technology to prevent future drug shortages

Some top drug companies are starting to take action on climate

Study points to new risk in gene therapy death of Terry Horgan

leisure time

fashion

hotspot

Apple is now the first public company to be valued at $3 trillion

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Cancer drug shortages should be causing more outrage

FDA panel issues narrow recommendation for Covid vaccine booster doses

Duchenne breakthrough therapy leaves behind pioneering families

IVG is promising — but it won’t replace IVF quite yet

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Medicare proposal to cover medical devices draws a mixed reaction

American woman, child freed after being kidnapped in Haiti last month

hotspot

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

The best solution to the drug shortages problem

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

IVG is promising — but it won’t replace IVF quite yet

WHO recommends second malaria vaccine

Police still searching for prisoner who escaped from NYC hospital

hotspot

knowledge

Wikipedia

focus